製品番号: HY-147014

Cyclic HPMPC

Cyclic HPMPC is a potent antiviral agent. Cyclic HPMPC can increase arterial oxygen saturation levels in lethal vaccinia virus (IHD strain)-infected mice. Cyclic HPMPC improves the outcome of congenital guinea pig cytomegalovirus (GPCMV) infection and decreases viral replication in guinea pig model.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 127757-45-3
分子式: C₈H₁₂N₃O₅P
分子量:261.17

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (267 KB)

Cyclic HPMPC 構造式

CAS 番号: 127757-45-3

価格（税別）

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
化学情報
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

Vaccinia virus, GPCMV^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
BSC-1	CC₅₀	>=672 μM Compound: cHPMPC	Cytotoxicity against african green monkey BSC1 cells Cytotoxicity against african green monkey BSC1 cells	[PMID: 17420214]
BSC-1	EC₅₀	18.5 μM Compound: cHPMPC	Antiviral activity against Simian virus 40 PML2 DAR in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Simian virus 40 PML2 DAR in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17420214]
BSC-1	EC₅₀	20.8 μM Compound: cHPMPC	Antiviral activity against Simian virus 40 PML1 EK in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Simian virus 40 PML1 EK in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17420214]
BSC-1	EC₅₀	22.2 μM Compound: cHPMPC	Antiviral activity against Simian virus 40 A2895 in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Simian virus 40 A2895 in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17420214]
C3H	EC₅₀	>20 μg/mL Compound: cHPMPC	Antiviral activity against MSV in C3H cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against MSV in C3H cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
CCRF-CEM	EC₅₀	>20 μg/mL Compound: cHPMPC	Antiviral activity against HIV1 3B in CEM cells assessed as reduction of virus-induced cytopathogenicity after 4 days Antiviral activity against HIV1 3B in CEM cells assessed as reduction of virus-induced cytopathogenicity after 4 days	[PMID: 17948980]
CCRF-CEM	EC₅₀	>20 μg/mL Compound: cHPMPC	Antiviral activity against HIV2 ROD in CEM cells assessed as reduction of virus-induced cytopathogenicity after 4 days Antiviral activity against HIV2 ROD in CEM cells assessed as reduction of virus-induced cytopathogenicity after 4 days	[PMID: 17948980]
CHO	IC₅₀	1100 μM Compound: Cyclic prodrug of Cidofovir	TP_TRANSPORTER: inhibition of 6-Carboxyfluorescein uptake in OAT1-expressing CHO cells TP_TRANSPORTER: inhibition of 6-Carboxyfluorescein uptake in OAT1-expressing CHO cells	[PMID: 10929807]
HEL	EC₅₀	>200 μg/mL Compound: cHPMPC	Antiviral activity against VSV in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against VSV in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.04 μg/mL Compound: cHPMPC	Antiviral activity against VZV 07-1 TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against VZV 07-1 TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.12 μg/mL Compound: cHPMPC	Antiviral activity against VZV OKA in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against VZV OKA in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.2 μg/mL Compound: cHPMPC	Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.21 μg/mL Compound: cHPMPC	Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.22 μg/mL Compound: cHPMPC	Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.39 μg/mL Compound: cHPMPC	Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.45 μg/mL Compound: cHPMPC	Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.76 μg/mL Compound: cHPMPC	Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	2.78 μg/mL Compound: cHPMPC	Antiviral activity against vaccinia virus Lederle in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against vaccinia virus Lederle in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	CC₅₀	≥76 μg/mL Compound: cHPMPC	Cytotoxicity against HEL cells assessed as cell growth after 3 days Cytotoxicity against HEL cells assessed as cell growth after 3 days	[PMID: 17948980]
HEL 299	CC₅₀	335 μM Compound: 2a, cHPMPC	Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis	[PMID: 17893157]
HEL 299	EC₅₀	6.1 μM Compound: 2a, cHPMPC	Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining	[PMID: 17893157]
HEL 299	EC₅₀	8.8 μM Compound: 2a, cHPMPC	Antiviral activity against Camelpox virus CML14 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining Antiviral activity against Camelpox virus CML14 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining	[PMID: 17893157]
HeLa	EC₅₀	>200 μg/mL Compound: cHPMPC	Antiviral activity against Coxsackie virus B4 in HeLa cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Coxsackie virus B4 in HeLa cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HeLa	EC₅₀	>200 μg/mL Compound: cHPMPC	Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HeLa	EC₅₀	>200 μg/mL Compound: cHPMPC	Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HFF	CC₅₀	100 μM Compound: 2, cHPMPC	Cytotoxicity against HFF cells Cytotoxicity against HFF cells	[PMID: 21641218]
HFF	IC₅₀	0.25 μM Compound: 2, cHPMPC	Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days	[PMID: 21641218]
HFF	IC₅₀	30 μM Compound: 2, cHPMPC	Antiviral activity against Cowpox virus Brighton infected in HFF cells assessed as reduction in plaque formation after 3 days Antiviral activity against Cowpox virus Brighton infected in HFF cells assessed as reduction in plaque formation after 3 days	[PMID: 21641218]
HFF	IC₅₀	40 μM Compound: 2, cHPMPC	Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells assessed as reduction in plaque formation after 3 days Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells assessed as reduction in plaque formation after 3 days	[PMID: 21641218]
HFF	IC₅₀	>100 μM Compound: 4, (S)-cHPMPC	Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay	[PMID: 21812420]
HFF	IC₅₀	0.25 μM Compound: 4, (S)-cHPMPC	Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay	[PMID: 21812420]
HFF	IC₅₀	30 μM Compound: 4, (S)-cHPMPC	Antiviral activity against Cowpox virus Brighton infected in HFF cells incubated for 3 days by plaque reduction assay Antiviral activity against Cowpox virus Brighton infected in HFF cells incubated for 3 days by plaque reduction assay	[PMID: 21812420]
HFF	IC₅₀	40 μM Compound: 4, (S)-cHPMPC	Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells incubated for 3 days by plaque reduction assay Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells incubated for 3 days by plaque reduction assay	[PMID: 21812420]
HFF	IC₅₀	50 μM Compound: 4, (S)-cHPMPC	Antiviral activity against HSV1 KOS infected in HFF cells incubated for 3 days by plaque reduction assay Antiviral activity against HSV1 KOS infected in HFF cells incubated for 3 days by plaque reduction assay	[PMID: 21812420]
KB	CC₅₀	>100 μM Compound: 2, cHPMPC	Cytotoxicity against human KB cells after 48 hrs by crystal violet staining technique Cytotoxicity against human KB cells after 48 hrs by crystal violet staining technique	[PMID: 21641218]
KB	IC₅₀	>100 μM Compound: 4, (S)-cHPMPC	Cytotoxicity against human KB cells after 48 hrs by crystal violet staining based spectrophotometric analysis Cytotoxicity against human KB cells after 48 hrs by crystal violet staining based spectrophotometric analysis	[PMID: 21812420]
Vero	EC₅₀	>200 μg/mL Compound: cHPMPC	Antiviral activity against Parainfluenza 3 in Vero cells reduction of virus-induced cytopathogenicity after 4 days Antiviral activity against Parainfluenza 3 in Vero cells reduction of virus-induced cytopathogenicity after 4 days	[PMID: 17948980]
Vero	EC₅₀	>200 μg/mL Compound: cHPMPC	Antiviral activity against Punta Toro virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days Antiviral activity against Punta Toro virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days	[PMID: 17948980]
Vero	EC₅₀	>200 μg/mL Compound: cHPMPC	Antiviral activity against Reovirus 1 in Vero cells reduction of virus-induced cytopathogenicity after 4 days Antiviral activity against Reovirus 1 in Vero cells reduction of virus-induced cytopathogenicity after 4 days	[PMID: 17948980]
Vero	EC₅₀	>200 μg/mL Compound: cHPMPC	Antiviral activity against Sindbis virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days Antiviral activity against Sindbis virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days	[PMID: 17948980]
Vero	EC₅₀	>200 μg/mL Compound: cHPMPC	Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]

化学情報

CAS 番号 127757-45-3
分子量 261.17
分子式 C₈H₁₂N₃O₅P
SMILES

O=C1N(C=CC(N)=N1)C[C@H](OC2)CO[P]2(O)=O
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (267 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Smee DF, et al. Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice. Int J Antimicrob Agents. 2004;23(5):430-437. [Content Brief]

[2]. Bravo FJ, et al. Effect of maternal treatment with cyclic HPMPC in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis. 2006;193(4):591-597. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Cyclic HPMPC

生物活性

製品説明

IC₅₀ & Target

Cellular Effect

化学情報

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

Bioz

Keywords

最近チェックした製品

Cyclic HPMPC

生物活性

製品説明

IC50 & Target

Cellular Effect

化学情報

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

Cyclic HPMPC 関連分類

HY-147014 関連分類

Bioz

Keywords

最近チェックした製品

IC₅₀ & Target